These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 28241822)

  • 1. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M; Townsend RR; Davies MJ; Vijapurkar U; Ren J
    Cardiovasc Diabetol; 2017 Feb; 16(1):29. PubMed ID: 28241822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.
    Davies MJ; Merton K; Vijapurkar U; Yee J; Qiu R
    Cardiovasc Diabetol; 2017 Mar; 16(1):40. PubMed ID: 28327140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
    Liu J; Pong A; Gallo S; Darekar A; Terra SG
    Cardiovasc Diabetol; 2019 May; 18(1):59. PubMed ID: 31064361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials.
    Blonde L; Woo V; Mathieu C; Yee J; Vijapurkar U; Canovatchel W; Meininger G
    Curr Med Res Opin; 2015 Nov; 31(11):1993-2000. PubMed ID: 26373629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Inagaki N; Goda M; Yokota S; Maruyama N; Iijima H
    Adv Ther; 2015 Nov; 32(11):1085-103. PubMed ID: 26530268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
    Chilton R; Tikkanen I; Cannon CP; Crowe S; Woerle HJ; Broedl UC; Johansen OE
    Diabetes Obes Metab; 2015 Dec; 17(12):1180-93. PubMed ID: 26343814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.
    Merton K; Davies MJ; Vijapurkar U; Inman D; Meininger G
    Curr Med Res Opin; 2018 Feb; 34(2):313-318. PubMed ID: 29022746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Lavalle-González FJ; Eliaschewitz FG; Cerdas S; Chacon Mdel P; Tong C; Alba M
    Curr Med Res Opin; 2016; 32(3):427-39. PubMed ID: 26579834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.
    John M; Cerdas S; Violante R; Deerochanawong C; Hassanein M; Slee A; Canovatchel W; Hamilton G
    Int J Clin Pract; 2016 Sep; 70(9):775-85. PubMed ID: 27600862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
    Baker WL; Buckley LF; Kelly MS; Bucheit JD; Parod ED; Brown R; Carbone S; Abbate A; Dixon DL
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28522675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus.
    Gavin JR; Davies MJ; Davies M; Vijapurkar U; Alba M; Meininger G
    Curr Med Res Opin; 2015; 31(9):1693-702. PubMed ID: 26121561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity.
    Davidson JA; Aguilar R; Lavalle González FJ; Trujillo A; Alba M; Vijapurkar U; Meininger G
    Ethn Dis; 2016 Apr; 26(2):221-8. PubMed ID: 27103773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
    Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
    Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension.
    Townsend RR; Machin I; Ren J; Trujillo A; Kawaguchi M; Vijapurkar U; Damaraju CV; Pfeifer M
    J Clin Hypertens (Greenwich); 2016 Jan; 18(1):43-52. PubMed ID: 26663712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
    Qiu R; Balis D; Xie J; Davies MJ; Desai M; Meininger G
    Curr Med Res Opin; 2017 Mar; 33(3):553-562. PubMed ID: 27977934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
    Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
    Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
    Weir MR; Kline I; Xie J; Edwards R; Usiskin K
    Curr Med Res Opin; 2014 Sep; 30(9):1759-68. PubMed ID: 24786834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
    Weir MR; Januszewicz A; Gilbert RE; Vijapurkar U; Kline I; Fung A; Meininger G
    J Clin Hypertens (Greenwich); 2014 Dec; 16(12):875-82. PubMed ID: 25329038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.